Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival

References

• PiccioliAPrandoniPVenous thromboembolism as first manifestation of cancerActa Haematol2001106131711549772
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWBullerHRDeep-vein thrombosis and the incidence of subsequent symptomatic cancerN Engl J Med1992327112811331528208
   PubMed Web of Science ®Google Scholar
• KhoranaAAFrancisCWCulakovaEFisherRIKudererNMLymanGHThromboembolism in hospitalized neutropenic cancer patientsJ Clin Oncol20062448449016421425
   PubMed Web of Science ®Google Scholar
• KhoranaAAFrancisCWCulakovaELymanGHRisk factors for chemotherapy-associated venous thromboembolism in a prospective observational studyCancer20051042822282916284987
   PubMed Web of Science ®Google Scholar
• RicklesFRLevineMNEpidemiology of thrombosis in cancerActa Haematol200110661211549771
   PubMed Web of Science ®Google Scholar
• FalangaARicklesFRManagement of thrombohemorrhagic syndromes (THS) in hematologic malignanciesHematology Am Soc Hematol Educ Program200716517118024625
   PubMedGoogle Scholar
• KhoranaAAKudererNMCulakovaELymanGHFrancisCWDevelopment and validation of a predictive model for chemotherapy-associated thrombosisBlood20081114902490718216292
   PubMed Web of Science ®Google Scholar
• FalangaABarbuiTRicklesFRLevineMNGuidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and HaemostasisThromb Haemost1993705405428259561
   PubMed Web of Science ®Google Scholar
• FalangaADonatiMBPathogenesis of thrombosis in patients with malignancyInt J Hematol20017313714411372723
   PubMed Web of Science ®Google Scholar
• FalangaAIacovielloLEvangelistaVLoss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acidBlood199586107210817620161
   PubMed Web of Science ®Google Scholar
• FalangaALevineMNConsonniRThe effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trialThromb Haemost19987923279459316
   PubMed Web of Science ®Google Scholar
• SeitzRRappeNKrausMActivation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosisBlood Coagul Fibrinolysis199342492548388741
   PubMed Web of Science ®Google Scholar
• WadaHSaseTYamaguchiMHypercoagulant states in malignant lymphomaExp Oncol20052717918516244577
   PubMed Web of Science ®Google Scholar
• FalangaAMarchettiMVignoliABalducciDClotting mechanisms and cancer: implications in thrombus formation and tumor progressionClin Adv Hematol Oncol2003167367816258469
   PubMedGoogle Scholar
• FalangaAPanova-NoevaMRussoLProcoagulant mechanisms in tumour cellsBest Pract Res Clin Haematol200922496019285272
   PubMed Web of Science ®Google Scholar
• HuttenBAPrinsMHGentMGinsbergJTijssenJGBullerHRIncidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysisJ Clin Oncol2000183078308310963635
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood20021003484348812393647
   PubMed Web of Science ®Google Scholar
• KhoranaAACancer and thrombosis: implications of published guidelines for clinical practiceAnn Oncol2009201619163019561038
   PubMed Web of Science ®Google Scholar
• HirshJWarkentinTEShaughnessySGHeparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safetyChest200111964S94S11157643
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med200334914615312853587
   PubMed Web of Science ®Google Scholar
• FareedJHoppensteadtDSchultzCBiochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profileCurr Pharm Des20041098399915078128
   PubMed Web of Science ®Google Scholar
• SamamaMMGerotziafasGTComparative pharmacokinetics of LMWHsSemin Thromb Hemost200026Suppl 1313811011804
   PubMed Web of Science ®Google Scholar
• ErikssonBISoderbergKWidlundLWandeliBTengbornLRisbergBA comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteersThromb Haemost1995733984017667822
   PubMed Web of Science ®Google Scholar
• FrydmanALow-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humansHaemostasis199626Suppl 224388707165
   PubMedGoogle Scholar
• BaraLSamamaMPharmacokinetics of low molecular weight heparinsActa Chir Scand Suppl198854365722847460
   PubMedGoogle Scholar
• CollignonFFrydmanACaplainHComparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)Thromb Haemost1995736306407495071
   PubMed Web of Science ®Google Scholar
• MismettiPLaporteSDarmonJYBuchmullerADecoususHMeta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeryBr J Surg20018891393011442521
   PubMed Web of Science ®Google Scholar
• DentaliFDouketisJDGianniMLimWCrowtherMAMeta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patientsAnn Intern Med200714627828817310052
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessmentENOXACAN Study GroupBr J Surg199784109911039278651
   PubMed Web of Science ®Google Scholar
• BergqvistDAgnelliGCohenATDuration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerN Engl J Med200234697598011919306
   PubMed Web of Science ®Google Scholar
• KhoranaAAStreiffMBFargeDVenous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to actionJ Clin Oncol2009274919492619720907
   PubMed Web of Science ®Google Scholar
• KakkarAKHaasSWolfHEnckeAEvaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudyThrombos Haemost200594867871
   PubMed Web of Science ®Google Scholar
• BergqvistDBurmarkUSFlordalPALow molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patientsBr J Surg1995824965017613894
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFSteinPDExtended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic reviewAnn Intern Med200113585886911712876
   PubMed Web of Science ®Google Scholar
• RasmussenMSJorgensenLNWille-JorgensenPProlonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label studyJ Thromb Haemost200642384239016881934
   PubMed Web of Science ®Google Scholar
• KakkarVVBalibreaJLMartinez-GonzalezJPrandoniPExtended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized studyJ Thromb Haemost201081223122920456751
   PubMed Web of Science ®Google Scholar
• SamamaMMCohenATDarmonJYA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study GroupN Engl J Med199934179380010477777
   PubMed Web of Science ®Google Scholar
• AlikhanRCohenATCombeSPrevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyBlood Coagul Fibrinolysis20031434134612945875
   PubMed Web of Science ®Google Scholar
• LeizoroviczACohenATTurpieAGOlssonCGVaitkusPTGoldhaberSZRandomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsCirculation200411087487915289368
   PubMed Web of Science ®Google Scholar
• CohenATTurpieAGLeizoroviczAOlssonCGVaitkusPTGoldhaberSZThromboprophylaxis with dalteparin in medical patients: which patients benefit?Vasc Med20071212312717615800
   PubMed Web of Science ®Google Scholar
• CohenATDavidsonBLGallusASEfficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialBMJ200633232532916439370
   PubMed Web of Science ®Google Scholar
• LevineMHirshJGentMDouble-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerLancet19943438868897908358
   PubMed Web of Science ®Google Scholar
• RiessHPelzerUDeutschinoffGA prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial [abstract]J Clin Oncol200927 abst LBA4506
   Google Scholar
• RiessHPelzerUHilbigARationale and design of PROSPECTCONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapyBMC Cancer2008836119055847
   PubMed Web of Science ®Google Scholar
• MaraveyasAWatersJRoyRGemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)Eur J Cancer Suppl20097362
   Web of Science ®Google Scholar
• HaasSKKakkarAKKemkes-MatthesBPrevention of Venous Thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer – results of the TOPIC studies [abstract]J Thromb Haemost20053 abst OR059
   Google Scholar
• PerryJRJulianJALaperriereNJPRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant gliomaJ Thromb Haemost201081959196520598077
   PubMed Web of Science ®Google Scholar
• AgnelliGGussoniGBianchiniCNadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyLancet Oncol20091094394919726226
   PubMed Web of Science ®Google Scholar
• GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest2008133381S453S18574271
   PubMed Web of Science ®Google Scholar
• Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)Int Angiol20062510116116763532
   PubMed Web of Science ®Google Scholar
• StreiffMBThe National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patientsThromb Res2010125Suppl 2S128S13320433992
   PubMed Web of Science ®Google Scholar
• MandalaMFalangaAPiccioliAVenous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)Crit Rev Oncol Hematol20065919420416837209
   PubMed Web of Science ®Google Scholar
• FargeDBosquetLKassab-ChahmiD2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working groupCrit Rev Oncol Hematol201073314619801193
   PubMed Web of Science ®Google Scholar
• MandalaMFalangaARoilaFVenous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the managementAnn Oncol201021Suppl 5v274v27620555096
   PubMed Web of Science ®Google Scholar
• LymanGHKudererNMPrevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology GuidelinesThromb Res2010125Suppl 2S120S12720433991
   PubMed Web of Science ®Google Scholar
• LymanGHKhoranaAAFalangaAAmerican Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancerJ Clin Oncol2007255490550517968019
   PubMed Web of Science ®Google Scholar
• KearonCKahnSRAgnelliGGoldhaberSRaskobGEComerotaAJAntithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed)Chest2008133454S545S18574272
   PubMed Web of Science ®Google Scholar
• Van DongenCJvan den BeltAGPrinsMHLensingAWFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismCochrane Database Syst Rev20044CD00110015495007
   PubMedGoogle Scholar
• AklEAVasireddiSRGunukulaSAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerCochrane Database Syst Rev20116CD006649
   Web of Science ®Google Scholar
• BullerHRDavidsonBLDecoususHSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismNew Engl J Med20033491695170214585937
   PubMed Web of Science ®Google Scholar
• BullerHRDavidsonBLDecoususHFondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialAnn Intern Med200414086787315172900
   PubMed Web of Science ®Google Scholar
• Van DoormaalFFRaskobGEDavidsonBLTreatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trialsThromb Haemost200910176276919350123
   PubMed Web of Science ®Google Scholar
• MeyerGMarjanovicZValckeJComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyArch Intern Med20021621729173512153376
   PubMed Web of Science ®Google Scholar
• DeitcherSRKesslerCMMerliGRigasJRLyonsRMFareedJSecondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodClin Appl Thromb Hemost20061238939617000884
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFBrantRFLong-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerAm J Med20061191062107217145251
   PubMed Web of Science ®Google Scholar
• Trujillo-SantosJNietoJATiberioGPredicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE RegistryThromb Haemost200810043543918766259
   PubMed Web of Science ®Google Scholar
• LeeAYParpiaSJulianJRicklesFRPrinsMLevineMRisk factors for recurrent thrombosis and anticoagulant – related bleeding in cancer patients [abstract]J Thromb Haemost20097 abst 107
   Google Scholar
• CarrierMLe GalGChoRTierneySRodgerMLeeAYDose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patientsJ Thromb Haemost2009776076519245418
   PubMed Web of Science ®Google Scholar
• KakkarAHedgesRWilliamsonRKakkarVPerioperative heparin-therapy inhibits late death from metastatic cancerInt J Oncol1995688588821556616
   PubMed Web of Science ®Google Scholar
• LebeauBChastangCBrechotJMSubcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” GroupCancer19947438458004580
   PubMed Web of Science ®Google Scholar
• SmorenburgSMHettiarachchiRJVinkRBullerHRThe effects of unfractionated heparin on survival in patients with malignancy – a systematic reviewThromb Haemost1999821600160410613641
   PubMed Web of Science ®Google Scholar
• HettiarachchiRJSmorenburgSMGinsbergJLevineMPrinsMHBullerHRDo heparins do more than just treat thrombosis? The influence of heparins on cancer spreadThromb Haemost19998294795210605808
   PubMed Web of Science ®Google Scholar
• LeeAYRicklesFRJulianJARandomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolismJ Clin Oncol2005232123212915699480
   PubMed Web of Science ®Google Scholar
• FalangaAThe effect of anticoagulant drugs on cancerJ Thromb Haemost200421263126515304028
   PubMed Web of Science ®Google Scholar
• KakkarAKLevineMNKadziolaZLow molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)J Clin Oncol2004221944194815143088
   PubMed Web of Science ®Google Scholar
• AltinbasMCoskunHSErOA randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancerJ Thromb Haemost200421266127115304029
   PubMed Web of Science ®Google Scholar
• KlerkCPSmorenburgSMOttenHMThe effect of low molecular weight heparin on survival in patients with advanced malignancyJ Clin Oncol2005232130213515699479
   PubMed Web of Science ®Google Scholar
• SiderasKSchaeferPLOkunoSHLow-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trialMayo Clin Proc20068175876716770976
   PubMed Web of Science ®Google Scholar
• KudererNMKhoranaAALymanGHFrancisCWA meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complicationsCancer20071101149116117634948
   PubMed Web of Science ®Google Scholar
• Lazo-LangnerAGossGDSpaansJNRodgerMAThe effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trialsJ Thromb Haemost2007572973717408406
   PubMed Web of Science ®Google Scholar
• IcliFAkbulutHUtkanGLow molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancerJ Surg Oncol20079550751217192920
   PubMed Web of Science ®Google Scholar
• Van DoormaalFFDi NisioMOttenHMRichelDJPrinsMBullerHRRandomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancerJ Clin Oncol2011292071207621502549
   PubMed Web of Science ®Google Scholar
• GriffithsGOBurnsSNobleSIMacbethFRCohenDMaughanTSFRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancerBMC Cancer2009935519807917
   PubMed Web of Science ®Google Scholar
• NorrbyKLow-molecular-weight heparins and angiogenesisAPMIS20061147910216519745
   PubMed Web of Science ®Google Scholar
• MarchettiMVignoliARussoLEndothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparinThromb Res200812163764517692905
   PubMed Web of Science ®Google Scholar
• KhoranaAASahniAAltlandODFrancisCWHeparin inhibition of endothelial cell proliferation and organization is dependent on molecular weightArterioscler Thromb Vasc Biol2003232110211512920044
   PubMed Web of Science ®Google Scholar
• VignoliAMarchettiMRussoLLMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cellsCancer Invest20112915316121261475
   PubMed Web of Science ®Google Scholar
• MousaSAMohamedSInhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitorThromb Haemost20049262763315351861
   PubMed Web of Science ®Google Scholar
• KhoranaAAFineRLPancreatic cancer and thromboembolic diseaseLancet Oncol2004565566315522652
   PubMed Web of Science ®Google Scholar
• ChewHKWunTHarveyDJZhouHWhiteRHIncidence of venous thromboembolism and the impact on survival in breast cancer patientsJ Clin Oncol200725707617194906
   PubMed Web of Science ®Google Scholar
• BarberaLThomasGErythropoiesis stimulating agents, thrombosis and cancerRadiother Oncol20109526927620219259
   PubMed Web of Science ®Google Scholar
• AgnelliGGeorgeDJFisherWThe ultra-low molecualr weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy : SAVE ONCO study [abstract]J Clin Oncol201129 abst LBA9014
   Google Scholar
• FalangaAMarchettiMHeparin in tumor progression and metastatic disseminationSemin Thromb Hemost20073368869418000796
   PubMed Web of Science ®Google Scholar
• LecumberriRMassutiBLopez VivancoGFontAGonzalez BillalabeitiaERocha EobotAIAdjuvant bemiparin in small cell lung cancer: results from the ABEL study [abstract]Thromb Res2010125Suppl 2 abst S163
   Google Scholar